Eli Lilly discovers, develops, manufactures, and markets prescription medicines across diabetes, obesity, oncology, immunology, and neuroscience. Its incretin-based treatments, including Mounjaro and Zepbound, are major growth products, while its broader portfolio includes oncology and immune-disease therapies. The company invests heavily in clinical development and manufacturing capacity to expand supply and support new indications.
Eli Lilly & Co. (LLY) has a MarketKingdoms composite score of 71.2 (B+), an B-range rating. It ranks 222nd of 1,866 covered companies, 8th of 78 in Healthcare (sector average 64.5) and 2nd of 13 in Drug Manufacturers - General. Scores as of 2026-10-25.
Its strongest lenses are KPI momentum at 99 (Healthcare average 78) and Expansion (growth) at 91 (Healthcare average 50). Its weakest lenses are Price (valuation) at 22 (sector average 50) and Quality (profitability) at 67 (sector average 50).
| Lens | Type | LLY | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 86 | 79 | 78 | 91st |
| KPI momentum | Research signal | 99 | 78 | 77 | 100th |
| Catalyst watch | Research signal | 72 | 74 | 71 | 24th |
| Price (valuation) | Fundamental lens | 22 | 50 | 53 | 14th |
| Expansion (growth) | Fundamental lens | 91 | 50 | 39 | 94th |
| Quality (profitability) | Fundamental lens | 67 | 50 | 60 | 73rd |
| Trend (momentum) | Fundamental lens | 74 | 50 | 55 | 82nd |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q2). After it the composite moved from 83.0 to 82.3. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 71.2.
The stock's valuation gap is +1.7%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 0.71, sector beta 0.22, industry beta 0.91; the factor model explains 54% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| AbbVie Inc. (ABBV) | 68.9 | B | -3.2% |
| GSK plc ADR (GSK) | 66.9 | B | -5.1% |
| Bristol-Myers Squibb Co. (BMY) | 66.2 | B | -11.0% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| Novo Nordisk ADR (NVO) | 62.8 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.0 | B- | -3.9% |
Eli Lilly & Co. financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.